Lessons for cannabinoid regulation from electronic nicotine delivery system product regulation

Area of Science:

• Public Health Policy
• Regulatory Science
• Cannabis Research

Background:

• Increasing state-level cannabis legalization for medical and recreational use.
• Growing momentum for federal cannabis legalization in the United States.
• The establishment of the Center for Tobacco Products (CTP) by the FDA in 2009 provides a regulatory precedent.

Purpose of the Study:

• To analyze the historical challenges faced by the FDA's Center for Tobacco Products (CTP) in regulating novel products.
• To draw lessons from the CTP's experience with electronic nicotine delivery systems (ENDS) for future cannabis regulation.
• To inform strategies for effective oversight and enforcement of cannabis products.

Main Methods:

• Historical review of the FDA's regulatory approach to tobacco products, particularly ENDS.
• Analysis of CTP's difficulties in defining regulatory scope and pathways.
• Examination of challenges in establishing timely and transparent product standards for marketing authorization.

Main Results:

• The FDA has encountered significant hurdles in establishing regulatory authority and clear review processes.
• The regulation of novel products like ENDS has been hampered by difficulties in setting product standards.
• These challenges offer valuable insights into potential pitfalls for cannabis product regulation.

Conclusions:

• Lessons learned from CTP's regulation of ENDS can guide the FDA's approach to cannabis.
• Proactive strategies are needed to define scope, select appropriate review pathways, and develop transparent standards for cannabis products.
• Effective regulatory frameworks are crucial for ensuring public health and safety amidst expanding cannabis markets.